Data as of Mar 07
| -0.52 / -0.94%|
Gentium SpA specializes in the manufacture of biopharmaceutical and medical drugs. It focuses on the development and manufacture of its primary product candidate, defibrotide, an investigational drug based on a mixture of single-stranded and double-stranded DNA extracted from pig intestines. The development of defibrotide has been focused on the treatment and prevention of a disease called hepatic veno-occlusive, or VOD, a condition that occurs when veins in the liver are blocked as a result of cancer treatments, such as chemotherapy or radiation, that are administered prior to stem cell transplantation. Gentium was founded by Laura Iris Ferro in 1993 and is headquartered in Villa Guardia, Italy.
|Khalid Islam||Chairman & Chief Executive Officer|
|Salvatore Calabrese||COO, CFO, Senior VP & Head-Investor Relations|
|Carin Heringa||Senior Vice President & Scientific Director|
|Stefano Giordani||Director-Human Resources|
|Filippo Cerruti||Head-Legal Affairs|